Skip main navigation

Military Health System

Clear Your Browser Cache

This website has recently undergone changes. Users finding unexpected concerns may care to clear their browser's cache to ensure a seamless experience.

Surveillance Snapshot: HIV Pre-Exposure Prophylaxis (PrEP) Prescriptions Within the Active Component of the U.S. Military, 2023

Image of 36019063. HIV Pre-Exposure Prophylaxis is a highly effective medicine for preventing HIV when used as prescribed.

Click on the table to access a 508-compliant PDF versionHIV Pre-Exposure Prophylaxis is a highly effective medicine for preventing HIV when used as prescribed, reducing the risk of HIV from sex by around 99% and the risk of HIV from injection drug use by at least 74%.1 The Department of Defense follows the U.S. Centers for Disease Control and Prevention HIV PrEP guidelines for identification of individuals eligible for HIV PrEP and their evaluation and monitoring.2 This Surveillance Snapshot was created to determine the number of active component service members prescribed PrEP during 2023. 

Data from the Defense Medical Surveillance System were used for this analysis.3 The population was restricted to ACSMs who received a PrEP prescription between January 1, 2023 and December 31, 2023. A PrEP prescription was defined as a record in the Pharmacy Data Transaction System or Theater Medical Data Store medication files within DMSS containing the drug name Truvada, Descovy, Emtricitabine, Tenofovir, Apretude, or Cabotegravir. Records with the names Disoproxil, Viread, or Emtricitabine or listing a therapeutic class of 081808 (antiretrovirals) were excluded, as those are HIV treatment medications. Additionally, a prescription record was excluded if an individual had a diagnosis of chronic hepatitis B or HIV on or before the prescription date, or a needlestick diagnosis within 30 days before or after the prescription date. 

An individual was counted once during the surveillance year. Counts were summarized by pharmacy type, demographic characteristics, service-related variables, and self-assessed sexually-transmitted infection risk (defined from the Periodic Health Assessment if completed within one year prior to the prescription date) (Table). 

There were 4,495 ACSMs with a prescription for HIV PrEP in 2023 (Table). The majority of prescriptions (79%) were obtained directly from a military clinic. The demographic groups with the highest numbers of prescriptions were 25-29 year olds (1,307), males (4,155), non-Hispanic Whites (1,772), and single, never married (2,865) ACSMs. In evaluating service-related characteristics, the highest number of prescriptions were among Army and Navy service members (1,526 and 1,452, respectively), enlisted (1,664 junior and 1,695 senior), communications/intelligence occupations (1,287), stationed in the U.S. (3,483), and in service for 3-10 years (2,164). The majority of service members with a prescription had a self-assessed risk for a STI (46%), but this information was unknown for 31% of the total PrEP recipients. 

These data provide an overview of ACSMs receiving HIV PrEP in 2023 and can be used to further evaluate subpopulations within the ACSM population that may have a missed opportunity for receiving HIV PrEP. 

Authors’ Affiliation

Epidemiology and Analysis Branch, Armed Forces Health Surveillance Division, Defense Health Agency: Dr. Eick-Cost, Dr. Mabila, and Dr. Ying 

Disclaimer

The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views, assertions, opinions, nor policies of the Defense Health Agency or the Department of Defense. 

References

  1. Centers for Disease Control and Prevention. Pre-Exposure Prophylaxis (PrEP). Accessed Feb. 26, 2024. https://www.cdc.gov/hiv/risk/prep/index.html
  2. Defense Health Agency. Defense Health Agency Procedural Instruction 6025.29: Provision of Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis (PrEP) for Persons at High Risk of Acquiring HIV Infection. Department of Defense. Updated Dec. 20, 2019. Accessed Feb. 26, 2024. https://www.health.mil/Reference-Center/DHA-Publications/2019/12/20/DHA-PI-6025-29 
  3. Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health. 2002;92(12):1900-1904.

You also may be interested in...

Article
Mar 1, 2024

Coverage of HIV Pre-Exposure Prophylaxis Within the Active Duty U.S. Military, 2023

This study provides the first estimate of HIV pre-exposure prophylaxis coverage in the U.S. military, defined as the proportion of the persons taking HIV PrEP out of the estimated number of persons who had indications for it, that is also comparable to U.S. civilian estimates. The population with indications for HIV PrEP was obtained from the ...

Article
Mar 1, 2024

Mid-Season Influenza Vaccine Effectiveness Estimates Among DOD Populations: A Composite of Data Presented at VRBPAC—the Vaccines and Related Biological Products Advisory Committee—2024 Meeting on Influenza Vaccine Strain Selection for the 2024-2025 Influenza Season

This is an introduction to a composite of three Surveillance Snapshots of Department of Defense data on mid-season influenza vaccine effectiveness that were presented at the 2024 VRBPAC meeting.

Article
Mar 1, 2024

Tobacco and Nicotine Use Among Active Component U.S. Military Service Members: A Comparison of 2018 Estimates from the Health Related Behaviors Survey and the Periodic Health Assessment

This study compared estimates of the prevalence of and risk factors for tobacco and nicotine use obtained from the 2018 Health Related Behaviors Survey and Periodic Health Assessment survey. The HRBS and the PHA are important Department of Defense sources of data on health behavior collected from U.S. military service members.

Report
Mar 1, 2024

MSMR Vol. 31 No. 3 - March 2024

.PDF | 1.34 MB

The March 2024 MSMR features a comparison of 2018 estimates from the HRBS and the PHA on tobacco and nicotine use among the U.S. military active component; followed by a report on coverage of HIV PrEP among active duty service members in 2023; supplemented by a Surveillance Snapshot of HIV PrEP prescriptions in 2023 in the active component; then a ...

Article
Jan 1, 2024

Ivermectin Prescription Fill Rates Among U.S. Military Members During the Coronavirus Disease 2019 (COVID-19) Pandemic

This report describes ivermectin prescription fill rates among U.S. active component service members over time during the early phases of the COVID-19 pandemic. Ivermectin prescription fill rates increased among active component service members early in the COVID-19 pandemic when misinformation about the effectiveness of ivermectin for prevention and ...

Skip subpage navigation
Refine your search
Last Updated: May 07, 2024
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Sign up on GovDelivery